Dyslipidemia | Treatment Algorithms: Claims Data Analysis | US | 2023

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9 inhibitors, are utilized to improve lipid levels with the goal of CV risk reduction. Statins dominate the dyslipidemia market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. However, the later-line treatment paradigm is evolving owing to the emergence of novel drug classes and more-positive outcomes data for the established agents. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated dyslipidemia patients are treated in the United States.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed dyslipidemia patients?
• How has PCSK9 inhibitors (Praluent, Repatha, and Leqvio) been integrated into the treatment algorithm, and what is its source of business?
• What percentage of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 2 years of diagnosis?
• What percentage of dyslipidemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Amarin, Esperion Therapeutics, Amgen, Novartis, Regeneron, Merck, Pfizer, AstraZeneca, Kowa Pharmaceuticals, Medicure Pharmaceuticals

Key drugs: Nexletol, Nexlizet, Vascepa, Repatha, Praluent, Leqvio, statins, fibrates, cholesterol absorption inhibitors.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.